What are your favorite cells? The stem variety? T-cells? I have a hard time choosing just one favorite. The first news item I feature talks new imaging methods to see deep inside any cells. Have a favorite organelle? The secret lives of cells — as never seen before, Nature. This news item covers newer imaging techniques …
Recommended reads: secrets of cells, T-cells, CRISPR Read More »
Clade Therapeutics has been pursuing the idea of using gene-editing to make universally compatible cells. The potential here is big. What if you could make cloaked stem cells that could be used to produce cellular therapies that could be given to most patients without fear of immune rejection? Clade Therapeutics Boston Business Journal covers the …
Clade Therapeutics pursues universal cells for cancer therapy Read More »
This edition of The Niche weekly reads has a bit more good news than usual including on stem cell transplants. It’s nice to see positive developments like some recipients of hematopoietic stem cell transplants being able to stay at home afterwards. Also, a reminder. You have until July 31 to enter our stem cell video …
The idea of stem cell therapy for diabetes is both exciting and in a way practical. By that I mean that there’s a good common sense foundation here. The idea of stem cell therapy for diabetes What do I mean? If medical researchers can replace lost beta cells in the pancreas using stem cell-produced beta …
Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more Read More »
There’s never enough time to get all of one’s science reading done, but we can try! It helps to have a list of “to-read” articles, whether actual research articles or media pieces. In the old days, I remember my mentors saying they literally had “piles” of journal articles on their coffee tables, bathrooms, bedrooms, etc. …
Weekly recommended science reads: stem cells, CRISPR, cancer & more Read More »
Making a CRISPR baby is a controversial idea to even propose now for many reasons, yet even after He Jiankui’s train wreck some people have seemed eager to try it including apparently a scientist whose name perhaps many readers here are not so familiar with in this context: Professor Hui Yang. ‘CRISPR baby guys’ Is …
Heads up on Hui Yang, another potential aspiring CRISPR baby researcher Read More »
ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the …
ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »
We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have a unique immune stealthiness. If such an approach was successful, patients would not need to …
Quick Q&A with ViaCyte CEO on CRISPR-stem cell work Read More »
By Anna Everette The title of this article is partially borrowed from a fascinating Lightning Presentation delivered by John Doench of Broad Institute at CRISPRcon this year. In his talk, Mr. Doench pointed out how we’ve been looking up to this promising technology for a while now, hoping it will deliver the anticipated results (see …
The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette Read More »
A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically, …
New #CRISPR updates: Editas to go public, patent issues, dragons & more Read More »